Mechanisms of nonpeptide ligand action at family B G proteincoupled receptors are largely unexplored. Here, we evaluated corticotropin-releasing factor 1 (CRF 1 ) receptor regulation by nonpeptide antagonists. The antagonist mechanism was investigated at the G protein-coupled (RG) The antagonist effect at RG is consistent with either strong allosteric inhibition or competitive inhibition at one of the peptide agonist binding sites. These findings demonstrate a novel effect of R-G interaction on the inhibitory activity of nonpeptide antagonists: Although the compounds are weak inhibitors of peptide binding to the R state, they strongly inhibit peptide agonist binding to RG. Strong inhibition at RG explains the antagonist properties of the compounds.
celerated [
3 H]NBI 35965 dissociation. These data are quantitatively consistent with nonpeptide antagonist and peptide ligand binding spatially distinct sites, with mutual, weak negative cooperativity (allosteric inhibition) between their binding. At the RG state the compounds near fully inhibited 125 I-sauvagine binding at low radioligand concentrations (79 -94 pM). NBI 35965 did not completely inhibit 125 I-sauvagine binding at high radioligand concentrations (82 Ϯ 1%, 1.3-2.1 nM) and slowed dissociation of 125 I-sauvagine and 125 I-CRF. The antagonist effect at RG is consistent with either strong allosteric inhibition or competitive inhibition at one of the peptide agonist binding sites. These findings demonstrate a novel effect of R-G interaction on the inhibitory activity of nonpeptide antagonists: Although the compounds are weak inhibitors of peptide binding to the R state, they strongly inhibit peptide agonist binding to RG. Strong inhibition at RG explains the antagonist properties of the compounds.
Corticotropin-releasing factor (CRF) is the principle mediator of the hypothalamic-pituitary-adrenal axis in the body's response to stress (Vale et al., 1981; Rivier and Vale, 1983) . This 41 amino-acid peptide binds to and activates the CRF 1 receptor (Chen et al., 1993) , which belongs to family B of the G protein-coupled receptor (GPCR) superfamily. The CRF 1 receptor is activated by peptides related in amino acid sequence to CRF, including urocortin I (UCN I) and the amphibian peptide sauvagine (Dautzenberg and Hauger, 2002) . Physiological studies have strongly implicated alteration of the CRF system in anxiety and depression (Holsboer, 1999; Gilligan et al., 2000; Grigoriadis et al., 2001) . Based on these studies CRF 1 receptor antagonism has been proposed as a potential treatment for these conditions. Many nonpeptide antagonists of the CRF 1 receptor have been described, such as CP 154,526 (Chen et al., 1997) , SC241 , NBI 27914 (Chen et al., 1996) , antalarmin (Webster et al., 1996) , DMP-696 (He et al., 2000) , and R121919 (Grigoriadis et al., 2000) . These compounds are CRF 1 receptor-selective, block CRF 1 receptor signaling in vitro, and demonstrate in vivo efficacy for reducing stress-related modulators and behaviors in animal models of neuropsychiatric disorders (Holsboer, 1999; Gilligan et al., 2000; Grigoriadis et al., 2001) .
Mechanisms of peptide-ligand interaction with CRF receptors have been extensively investigated (Perrin and Vale, 1999; Grigoriadis et al., 2001) . The extreme C terminus of CRF is required for high-affinity binding (Vale et al., 1981) , whereas the N-terminal region of CRF is required for receptor activation (Rivier et al., 1984; Nielsen et al., 2000) . These findings have been used to develop a high-affinity peptide antagonist, astressin [cyclo(30 -33) Nle 21, 38 ,Glu 30 ,Lys 33 ]CRF(12-41) (Miranda et al., 1994) ]. CRF receptors are predicted to consist of a large extracellular N-terminal domain (N-domain), connected to the juxtamembrane region consisting of the transmembrane domains and intervening loops (J-domain) (Perrin and Vale, 1999; Grigoriadis et al., 2001) . The N-domain is a determinant of high-affinity peptide ligand binding (Liaw et al., 1997b; Dautzenberg et al., 1998; Perrin et al., 1998; Wille et al., 1999; Assil et al., 2001; Hofmann et al., 2001; Perrin et al., 2001 ). Regions and residues in the J-domain are involved in receptor activation by peptide ligands Nielsen et al., 2000; Assil et al., 2001 ) and contribute to ligand binding affinity (Liaw et al., 1997a,b; Perrin et al., 1998; Sydow et al., 1999) . Collectively, these results suggest that the N-terminal portion of the ligand binds the J-domain of the receptor (for activation), and the C-terminal ligand region binds the receptor's N-domain (for high-affinity binding).
In contrast to peptide ligands, little is known regarding the receptor interactions of nonpeptide ligands for the CRF 1 receptor. Receptor mutation has suggested that NBI 27914 binds to a site at least partially distinct from the peptide ligand binding regions (Liaw et al., 1997a) . SC241 modulates peptide ligand dissociation and reduces E max in adenylyl cyclase assays (Zaczek et al., 1997) . Thus, some qualitative evidence suggests that nonpeptide ligands may act allosterically to inhibit peptide ligand binding to the CRF 1 receptor. (Allosterism is defined here as the ability of ligand binding to one site to influence the binding of ligand to a second, at least partially distinct site on the receptor.) However, little or no quantitative data exist to support this hypothesis.
In this study, we have comprehensively evaluated the functional mechanism by which nonpeptide ligands antagonize peptide ligand binding to the CRF 1 receptor. We have applied a quantitative model to ligand binding data to test the hypothesis that nonpeptide antagonists inhibit peptide ligand binding to the CRF 1 receptor via an allosteric mechanism. Moreover, the extent to which receptor-G protein interaction affects the nonpeptide antagonist mechanism is unknown. (The pharmacological behavior of GPCR ligands is frequently dependent upon the conformational state of the receptor; Kenakin, 2002) . Here, the effect of receptor-G protein interaction has been investigated and shown to profoundly affect the inhibitory activity of the compounds. Finally, antagonist mechanisms have previously only been assessed indirectly using unlabeled compounds. In this study the use of [ 3 H]NBI 35965 enabled direct measurement of the antagonist's receptor binding kinetics and allowed us to validate the proposed allosteric mode of action of the compound.
Materials and Methods
Materials. The peptides rat/human CRF, rat UCN I, sauvagine, astressin, and [Tyr 0 ]astressin were synthesized by solid phase methodology on a Beckman Coulter 990 peptide synthesizer (Fullerton, CA) using t-Boc-protected amino acids. The assembled peptide was deprotected with hydrogen fluoride. The crude peptide product was purified by preparative HPLC, and the purity of the final product was assessed by analytical HPLC and mass spectrometric analysis using an ion-spray source. The peptides were dissolved in 10 mM acetic acid/0.1% bovine serum albumin (BSA) at a concentration of 1 mM and stored in 10-to 20-l aliquots at Ϫ80°C. Aliquots were used once and any remaining solution discarded. (Grigoriadis et al., 1994) (termed L-CRF 1 ) were grown in Dulbecco's modified Eagle's medium, supplemented with 10% fetal bovine serum, 2 mM glutamine, 1 mM sodium pyruvate, 10 mM HEPES, 50 IU/ml penicillin, 50 g/ml streptomycin, and 200 g/ml G418.
Isolation of Cell Membranes. L-CRF 1 cells were grown in 500-cm 2 tissue culture plates until confluent. The medium was removed and the cell monolayer washed once with 50 ml of DPBS per plate. Cells were then dislodged by scraping in 50 ml of DPBS per plate. Cells were collected in 250-ml centrifuge tubes and then pelleted by centrifugation at 800g for 10 min at 4°C in a Beckman Coulter GS-6R centrifuge. The cell pellet was then resuspended in assay buffer [DPBS (1.5 mM KH 2 PO 4 , 8.1 mM Na 2 HPO 4 , 2.7 mM KCl, and 138 mM NaCl) supplemented with 10 mM MgCl 2 , 2 mM ethylene glycolbis [␤-aminoethyl] -N,N,NЈ,NЈ-tetraacetic acid, pH 7.4, with NaOH], using 3 ml of buffer/500-cm 2 plate of cells. Cell lysis was then performed using a pressure cell, applying N 2 at a pressure of 900 psi for 30 min at 4°C. Unbroken cells and larger debris were removed by centrifugation at 1200g for 10 min at 4°C in a Sorvall RC 5C centrifuge (SM24 rotor). The cell membrane supernatant was then centrifuged at 45,000g (Sorvall RC 5C centrifuge, SM24 rotor) and the resulting membrane pellet homogenized in assay buffer using a Biospec Products (Bartlesville, OK) model 985-370 tissue homogenizer on setting 5 for 30 s on ice. Membrane protein concentration was determined using the Coomassie method (Pierce Chemical, Rockford, IL), using BSA as the standard. Membranes were stored at Ϫ80°C before use.
Radioligand Binding Assays. Equilibrium binding of unlabeled ligands was measured in duplicate by inhibition of radioligand binding ( 125 I-sauvagine, 125 I-CRF, 125 I-astressin, or [ 3 H]NBI 35965) to L-CRF 1 cell membranes. Buffer (30 l), 20 l of unlabeled ligand, 50 l of radioligand, and 100 l of L-CRF 1 cell membranes were sequentially added to low protein-binding Corning) . In some assays guanosine 5Ј-O-(3-thiotriphosphate) (GTP␥S, 30 M final concentration) was included, added in the 30 l of buffer, to measure ligand binding to the G protein-uncoupled state of the receptor. In some assays GTP␥S and NBI 35965 were included, added sequentially in volumes of 10 and 20 l, respectively. The concentration of radioligand used was approximately 90 pM or 2 nM for 125 I-sauvagine, 200 pM for 125 I-sauvagine in the presence of GTP␥S, 90 pM for 125 I-CRF, 60 pM for 125 I-astressin, and 2.5 nM for [ 3 H]NBI 35965. The amount of membrane used per well was 2 to 5 g for the peptide radioligands and 10 g for [ 3 H]NBI 35965. Dilution series of unlabeled ligands were prepared in low protein-binding 96-well plates. The assay mixture was incubated for 2 h at 21°C, a time period long enough to allow radioligand binding to closely approach its equilibrium binding asymptote (determined from radioligand association experiments; t 1/2 determined from the observed association rate constant of 21, 5, and 15 min for 125 I-sauvagine, 125 I-astressin, and [ 3 H]NBI 35965, respectively). Bound and free radioligand were then separated by rapid filtration, using UniFilter GF/C filters (PerkinElmer Life Sciences) on a UniFilter-96 vacuum manifold (PerkinElmer Life Sciences). GF/C filters were pretreated for 20 to 40 min with 0.1% polyethylenimine in DPBS and then pretreated, immediately before harvesting, by filtration with 0.2 ml/well 1% BSA/0.01% Triton X-100 in DPBS. The filter was washed four times with 0.2 ml/well 0.01% Triton X-100 in DPBS and then dried under electric fans for 40 min to 1 h. After addition of scintillation fluid (40 l/filter disc, Microscint 20; PerkinElmer Life Sciences), scintillation counts were measured in a Topcount NXT. The cpm resulting from emission of beta particles from 3 H and Auger electrons from 125 I were converted to dpm, using the predetermined counting efficiency of 30%. In all assays total radioligand bound to the filter (total binding) was less than 20% of the total amount of radioligand added (6-15% for  125 I-sauvagine, 2-3% for  125 I-sauvagine with In radioligand dissociation assays, radioligand was first equilibrated with L-CRF 1 cell membranes and then a large excess of unlabeled analog of the radioligand added, to prevent radioligand association. Dissociation of the radioligand was measured by determining the radioligand bound at various time points (in duplicate) after initiation of the dissociation phase of the experiment. Test agents for modulation of radioligand dissociation were added at the same time as the unlabeled analog of the radioligand. For the equilibration phase, the following were added sequentially to low proteinbinding 96-well plates: 25 l of buffer or GTP␥S in buffer, 50 l of radioligand, and 100 l of L-CRF 1 cell membranes. The concentration of radioligand used was approximately 90 pM for 125 I-sauvagine, 90 pM for 125 I-CRF, 60 pM for 125 I-astressin, and 2.5 nM for [ 3 H]NBI 35965. After a 2-h incubation at 21°C, a large excess of the unlabeled analog of the radioligand was added (in 25 l, 320 nM final concentration for peptide ligands and 1 M for NBI 35965). Test agents for modulation of radioligand dissociation were diluted from 40 times concentrated stocks into the unlabeled ligand solution. In each experiment, unlabeled ligand was added nearly simultaneously to each well, and all wells for an individual time point were harvested simultaneously. Nonspecific binding was measured by including the unlabeled analog in the equilibration phase of the experiment, and total binding (without unlabeled peptide or test agent) was measured by adding 25 l of buffer at the initiation of the dissociation phase of the assay. Nonspecific binding and total binding was measured at each time point in the dissociation phase.
Data Analysis. Inhibition of radioligand binding was fitted to one-affinity state or two-affinity state competition models, and the best fit determined using a partial F-test, using GraphPad Prism 3.0 (GraphPad Software Inc., San Diego, CA). K i was calculated using the method of Cheng and Prusoff (1973) . Radioligand saturation data were fitted to one-and two-site saturation equations using Prism 3.0, and the best fit determined using a partial F-test. (In all cases, the one-site model provided the best fit to the data (p Ͼ 0.05).) Radioligand dissociation data were analyzed using the following monoexponential and biexponential decay functions, and the best fit determined using a partial F-test, using Prism 3.0: 
Results
The mechanism of receptor regulation by nonpeptide antagonists was investigated by measuring ligand binding to the CRF 1 receptor. In this study, we evaluated the binding mechanism at the different conformational states of the CRF 1 receptor in Ltk Ϫ cell membranes. Ligand binding to the CRF 1 receptor is regulated by receptor-G protein interaction, an almost universal characteristic of GPCRs. The uncoupled receptor state (R) binds agonists with lower affinity and can be measured using the antagonist 125 I-astressin with 30 M GTP␥S present. The receptor bound to G protein (RG) occupies a state with high affinity for agonists and can be measured using the agonist radioligand 125 I-sauvagine. A third, minor state of the CRF 1 receptor was identified (named here as R O ), which is insensitive to GTP␥S but which binds agonist with high affinity. Modulation of Equilibrium Peptide Antagonist Binding to the R State of the CRF 1 Receptor by Nonpeptide Antagonists. We first examined the regulation of the R state of the CRF 1 receptor. Initially, the effect of nonpeptide antagonists on radiolabeled antagonist binding was evaluated, by measuring the effect of nonpeptide antagonists on equilibrium 125 I-astressin binding to L-CRF 1 membranes in the presence of 30 M GTP␥S.
125 I-Astressin binding was not affected by any concentration of GTP␥S tested (31.6 pM-100 M), and the K i value of unlabeled astressin was not significantly different for the R and RG states.
1 Antalarmin, NBI 27914, NBI 35965, and DMP-696 failed to completely inhibit specific 125 I-astressin binding to the R state ( Fig. 1A) . At saturating concentrations (defined as the lower plateau of the inhibition curve), the compounds inhibited 20 to 32% of 125 I-astressin binding ( Fig. 1A ; Table 1 ). All three antagonists displayed high affinity for inhibiting 125 I-astressin binding (1.1-8.6 nM; Table 1 ). The partial inhibition of radioligand binding is suggestive of an allosteric mode of inhibition: Binding of 125 I-astressin to receptor saturated with nonpeptide antagonist is consistent with at least partially distinct binding sites for the two ligands (at the R state). In the Appendix, the 125 I-astressin inhibition data are analyzed using a quantitative model of allosteric modulation, the allosteric ternary complex model (Stockton et al., 1983; Ehlert, 1988; Lazareno and Birdsall, 1995) . The fitted parameter estimates are presented in Table 1 .
Modulation of Peptide Antagonist Dissociation from the R State of the CRF 1 Receptor by Nonpeptide Antagonist. Modulation of peptide antagonist binding to R was investigated further in 125 I-astressin dissociation experiments. NBI 35965 accelerated dissociation of 125 I-astressin from L-CRF 1 membranes (with 30 M GTP␥S present) in a concentration-dependent, saturating manner, consistent with allosteric modulation of 125 I-astressin binding (Fig. 1B) . NBI 35965 reduced the t 1/2 for 125 I-astressin dissociation with a pEC 50 value of 7.89 Ϯ 0.33 (EC 50 ϭ 13 nM; Fig. 1C ), lower than the compound's potency for displacing equilibrium 125 I-astressin binding to R (pK i ϭ 8.87, K i ϭ 1.4 nM; Table 1 ). The compound produced a maximal reduction of t 1/2 of 1.5 Ϯ 0.1-fold (Fig. 1C) .
125 I-Astressin dissociation was biphasic in the absence and presence of NBI 35965 (Fig. 1,  legend) . The mechanism underlying biphasic dissociation is unknown. The observation might be due to multiple points of contact between 125 I-astressin and the receptor. (Fig. 2) . NBI 35965 produced a rightward shift of the sauvagine, CRF, and UCN I inhibition curve (Fig. 2) , indicating inhibition of agonist binding to the R state. However, incremental increases of NBI 35965 did not produce incremental increases of agonist IC 50 , as predicted by a competitive interaction between the two ligands. Rather, the extent of increase of agonist IC 50 seemed to approach a limiting value (Fig. 2) . In consequence, the fold-shift of agonist IC 50 at 100 nM NBI 35965 (4.0 Ϯ 0.8, 6.5 Ϯ 2.2 and 7.1 Ϯ 0.8 for sauvagine, CRF and UCN I, respectively) was much less than the fold-increase of agonist affinity predicted by competitive inhibition (57-fold, calculated using the Cheng-Prusoff equation; Cheng and Prusoff, 1973) , assuming the affinity of NBI 35965 for the R state is 1.8 nM (Table 1 ). These observations are consistent with an allosteric interaction between NBI 35965 and agonist ligands at the R state: The limited increase of agonist IC 50 suggests that binding of NBI 35965 only partially reduces the affinity of agonist binding to the receptor. In the Appendix, the allosteric ternary complex model has been used to quantify the allosteric effect, and the fitted parameters are provided in Fig. 4A ; 5 Ϯ 8% inhibition at 10 M GTP␥S). In addition, the affinity of unlabeled NBI 35965 was not significantly different for R and RG states (see below). Association and dissociation of [ 3 H]NBI 35965 were both described by monoexponential processes, consistent with a single-affinity state of binding (Fig.  3, B and C) . Steady-state binding, after equilibration, was reasonably stable for up to 3.5 h (Fig. 3C) . Nonspecific binding did not change during the time course of [ 3 H]NBI 35965 association and dissociation (Fig. 3, B and C) . The association rate constant was 1.2 ϫ 10 7 Ϯ 0.7 ϫ 10 7 M Ϫ1 min Ϫ1 (n ϭ 4). The lower limit of the [ 3 H]NBI 35965 dissociation curve closely approached nonspecific binding (Fig. 3C) (Fig. 1A) were fitted to the allosteric ternary complex model (eq. 1, see Appendix). For the peptide agonists (sauvagine, CRF, and UCN I) K N and ␣ were estimated by fitting the data of Fig. 2 to the allosteric ternary complex model (eq. 3). Data are the mean Ϯ S.E.M (n ϭ 3). In all analyses the affinity constant of 125 I-astressin was fixed at the value measured in saturation experiments (1.43 ϫ 10 10 M Ϫ1 ). b Significantly different from the astressin ␣ value. c Significantly different from the CRF ␣ value. d Significantly different from the UCN I ␣ value. Equation 3 also provides estimates of unlabeled agonist affinity for the R state (pK L ). To test the validity of the fit to eq. 3, these values were compared with those measured in the absence of a second, unlabeled ligand. The fitted value of agonist affinity (pK L ) from eq. 3 (Fig. 2) bound with high affinity to the R state (0.6-2.1 nM; Fig. 4A ; Table 1 ). The compounds bound with similar affinity in displacing [
3 H]NBI 35965 binding to the high-affinity state, although antalarmin showed a trend of higher affinity than the other compounds. In functional assays (inhibition of sauvagine-stimulated cAMP accumulation in whole cells) NBI 27914, NBI 35965, and DMP-696 were equivalently potent to each other (pIC 50 values of 6.67 Ϯ 0.13, 7.11 Ϯ 0.12, and 7.31 Ϯ 0.20, respectively, n ϭ 6, 5, and 3, respectively). Antalarmin was slightly more potent (pIC 50 of 7.79 Ϯ 0.10, n ϭ 3).
The (Fig. 4B) (Fig. 5, A-C (Fig. 5D ). (Dissociation  of [ 3 H]NBI 35965 was monophasic in the absence and presence of peptide ligands.) The pEC 50 value for sauvagine, CRF, and UCN I was 6.24 Ϯ 0.04, 6.38 Ϯ 0.01, and 7.33 Ϯ 0.02 respectively, with a corresponding maximal increase of the dissociation rate of 3.6 Ϯ 0.5-, 5.3 Ϯ 0.1-, and 7.0 Ϯ 0.1-fold (n ϭ 2). A saturating concentration of astressin (3.2 M) did not significantly affect the dissociation rate of [ 3 H]NBI 35965 (Fig. 5D ). This finding is in contrast to the modulation of 125 I-astressin dissociation by NBI 35965 (Fig.  1) . The reason for this difference is not presently clear.
Modulation of Equilibrium Peptide Agonist Binding to the RG State of the CRF 1 Receptor by Nonpeptide
Antagonists. Modulation of agonist binding to RG was first evaluated in equilibrium binding assays, by measuring inhibition of 125 I-sauvagine binding to L-CRF 1 cell membranes in the absence of GTP␥S. In these assays it was not possible to detect the RG state as a homogeneous population of binding sites, owing to the detection of the R O state by 125 I-sauvagine.
1 However, we were able to maximize the occupancy of RG relative to R O by using a low concentration of the radioligand (90 pM), because 125 I-sauvagine binds with higher The mechanism by which nonpeptide antagonists affect equilibrium agonist binding to RG was investigated using NBI 35965. We tested for the presence of deviation from competitive inhibition, by increasing the concentration of 125 I-sauvagine in the inhibition assay. As described in the Appendix and in Stockton et al. (1983) and Ehlert (1988) , for an allosteric inhibitor the allosteric effect can become manifest as incomplete radioligand inhibition as the radioligand concentration is increased. When the 125 I-sauvagine dose was increased to 1.3 to 2.1 nM (30-49-fold the K d value of 43 pM), NBI 35965 incompletely inhibited radioligand binding (82 Ϯ 1% inhibition; Fig. 6B ), suggesting a more complex interaction than competitive inhibition.
Modulation of Peptide Agonist Dissociation from the RG State of the CRF 1 Receptor by Nonpeptide Antagonist. Deviation from competitive inhibition of peptide binding to RG by NBI 35965 was tested further in radiolabeled agonist dissociation experiments. NBI 35965 slowed dissociation of 125 I-sauvagine and 125 I-CRF from L-CRF 1 cell membranes in a concentration-dependent and saturating manner (Fig. 7, A and B) . The slowing of radiolabeled agonist dissociation by NBI 35965 was in marked contrast to the effect of GTP␥S, which accelerated dissociation of 125 I-sauvagine and 125 I-CRF (Fig. 7, A and B) .
The effect of NBI 35965 on radiolabeled agonist dissociation was quantified by measuring the half-time (t 1/2 ) of radiolabeled agonist dissociation in the presence of a range of NBI 35965 concentrations (Fig. 7C) . The antagonist increased the dissociation t 1/2 of 125 I-sauvagine and 125 I-CRF with a pEC 50 value of 6.87 Ϯ 0.31 and 7.28 Ϯ 0.27, respectively (n ϭ 3; EC 50 values of 130 and 52 nM, respectively). Therefore, higher concentrations of NBI 35965 are required c The ␣ value for the two ligands was not significantly different (p ϭ 0.45; two-tailed Student's t test). Data are the mean Ϯ S.E.M. (n ϭ 7 for sauvagine, n ϭ 5 for CRF, n ϭ 4 for UCN I, and n ϭ5 for astressin). I-sauvagine concentration were also fitted to the allosteric ternary complex model (eq. 1), for which the fitted curve is superimposable on the fit to the single-affinity state inhibition model. The mean of the fitted value to eq. 1 were as follows: ␣ ϭ 0.0056 Ϯ 0.0012 and pK N ϭ 9.15 Ϯ 0.06. These fitted mean parameters for the high concentration of to modulate dissociation of the agonist from RG (Fig. 7C) than to inhibit equilibrium binding of the agonist to RG (Fig.  6B) . The maximum fold-increase of t 1/2 was 4.6 Ϯ 1.5 and 2.2 Ϯ 0.4 for 125 I-sauvagine and 125 I-CRF, respectively (Fig.  7C) .
In the absence of NBI 35965, 125 I-sauvagine and 125 I-CRF dissociation was biphasic (Fig. 7, legend) . Dissociation was also biphasic in the presence of all concentrations of NBI 35965 tested. The mechanism underlying biphasic agonist dissociation is unknown, but the observation may be related to the detection of a small amount of the R O state as well as the RG state by 125 I-sauvagine. Modulation of Equilibrium Peptide Agonist Binding to the R O State of the CRF 1 Receptor by Nonpeptide Antagonists. A minor fraction of the CRF 1 receptor population in L-CRF 1 cell membranes (16%) exists in a conformation that binds agonists with high affinity, but which is insensitive to GTP␥S (termed R O ).
1 The pharmacological profile of nonpeptide antagonist activity at this state was measured by inhibition of 125 I-sauvagine binding to L-CRF 1 cell membranes in the presence of 30 M GTP␥S. In this assay, antalarmin NBI 27914, NBI 35965, and DMP-696 fully inhibited binding of a low concentration of 125 I-sauvagine (150-240 pM), displaying high affinity for this effect ( Fig. 8 ; Table  1 ).
Comparison of Nonpeptide Antagonist Affinity for R, RG, and R O States of the CRF 1 Receptor. The nonpeptide antagonist affinity for these three states of the CRF 1 receptor was compared using the K i value for inhibition of [ 3 H]NBI 35965 binding in the presence of GTP␥S, 125 I-sauvagine binding, and 125 I-sauvagine in the presence of GTP␥S, respectively. None of the antagonists appreciably discriminated between these states: the largest difference of affinity was only 3.3-fold (between RG and R O for NBI 35965; Table  1 ). The nonpeptide antagonist affinity for R, RG, and R O was not significantly different for antalarmin, NBI 27914, and DMP 696 (p ϭ 0.10, 0.09, and 0.12, respectively; single-factor ANOVA). The affinity values were significantly different for NBI 35965 (p ϭ 0.0057; single-factor ANOVA): the affinity for R O (4.6 nM) was significantly different from the affinity for R (1.8 nM; p Ͻ 0.01) and RG (1.4 nM; p Ͻ 0.01, post hoc analysis using the Newman-Keuls test).
Discussion
Numerous nonpeptide antagonists have been developed for the CRF1 receptor, as potential therapies for CRF-associated disorders such as anxiety and depression (Holsboer, 1999; Gilligan et al., 2000; Grigoriadis et al., 2001 ). However, little is known regarding their functional mechanism of action at I-sauvagine (A) and 125 I-CRF (B) from L-CRF 1 cell membranes was measured as described under Materials and Methods, in the absence of antagonist or in the presence of a range of concentrations of NBI 35965. The curves are fits to a biexponential decay function, which provided a significantly better fit than a monoexponential function in all cases (p Ͻ 0.05). In the absence of NBI 35965, the mean fitted parameters for 125 I-sauvagine dissociation were P (fast) ϭ 63 Ϯ 9%, k Ϫ1(fast) ϭ 0.20 Ϯ 0.09 min Ϫ1 , and k Ϫ1(slow) ϭ 0.0098 Ϯ 0.0041 min Ϫ1 and for 125 I-CRF were P (fast) ϭ 38 Ϯ 3%, k Ϫ1(fast) ϭ 0.24 Ϯ 0.07 min Ϫ1 , and k Ϫ1(slow) ϭ 0.0089 Ϯ 0.00051 min Ϫ1 . Data points are mean Ϯ range of duplicate measurements. Data are from representative experiments that were performed three times with similar results. C, effect of NBI 35965 on the half-time (t 1/2 ) of the receptor level. The aim of this study was to quantitatively evaluate the mechanism of action of four nonpeptide antagonists: antalarmin, NBI 27914, NBI 35965, and DMP-696. In addition, we compared the effects of these molecules at the G protein-coupled (RG) and uncoupled (R) states of the CRF 1 receptor in Ltk Ϫ cell membranes. 3) Antalarmin, NBI 27914, NBI 35965, and DMP-696 likely bind a common site on the receptor and modulate peptide ligand binding in a quantitatively similar manner. 4) Nonpeptide antagonists bind with similar affinity to the R and RG state. 5) At the RG state nonpeptide antagonists strongly inhibited peptide agonist binding (in marked contrast to their behavior at the R state), explaining their antagonist effect. 6) At the RG state deviations from simple competitive inhibition were detected. As described below, findings 1 and 2 for the R state support an allosteric mechanism by which nonpeptide antagonist and peptide ligand inhibit each other's binding. Findings 5 and 6 for the RG state are consistent with either strong allosteric inhibition or competitive inhibition at one of the peptide agonist binding sites.
At the R state of the CRF 1 receptor, four observations were consistent with an allosteric mechanism for nonpeptide antagonism, in which peptide and nonpeptide ligands bind to at least partially distinct sites (Appendix; Stockton et al., 1983; Ehlert, 1988; Lazareno and Birdsall, 1995) Table 1 ). In the second potential model, two binding regions of the peptide ligand bind to two corresponding, spatially independent sites on the receptor (site 1 and site 2). This model is consistent with the known peptide binding mechanism (Perrin and Vale, 1999; Grigoriadis et al., 2001 ). In this model nonpeptide antagonist competitively inhibits peptide binding to the site 1, without affecting peptide binding to site 2. Examination of this model using simulated data indicates that it allows for partial inhibition of peptide binding by nonpeptide antagonist, partial inhibition of [ 3 H]NBI 35965 binding by peptide ligand (provided that the peptide affinity for the site 1 is weak compared with site 2), and modulation of peptide ligand dissociation.
1 However, the model does not allow modulation of [ 3 H]NBI 35965 dissociation by peptide ligand. Therefore, of the models considered, only allosteric modulation fully accounts for the data obtained for the R state of the CRF 1 receptor.
For other GPCRs, allosteric modulation is consistent with a theoretical model, the allosteric ternary complex model (Stockton et al., 1983; Ehlert, 1988; Lazareno and Birdsall, 1995; Trankle et al., 1999; Leppik and Birdsall, 2000) . In this model, the behavior of the allosteric ligand (e.g., NBI 35965) is defined by its affinity for the receptor and by the cooperativity between binding of allosteric and orthosteric ligand (e.g., CRF). Data for the R state of the CRF 1 receptor were fitted to the allosteric ternary complex model to quantify the allosteric effect. The analysis indicated negative cooperativity between NBI 35965 and peptide agonist binding. The negative cooperativity was weak; the greatest effect of NBI 35965 was on UCN I binding (␣ ϭ 0.11, indicating that NBI 35965 binding reduces the affinity of UCN I by only 9-fold). Equilibrium binding and radioligand dissociation data are in good agreement with the model (Appendix), indicating that allosteric modulation is sufficient to account for the data for the R state. In particular, the data are fully consistent with (Tables 2 and 3 ; Appendix). This reciprocal relationship has been demonstrated for gallamine and N-methylscopolamine at the M 2 muscarinic acetylcholine receptor (Trankle et al., 1999) .
At the RG state, the effect of the nonpeptide antagonists on peptide agonist binding differed markedly from the R state. Nonpeptide antagonists antalarmin, NBI 27914, NBI 35965, and DMP-696 strongly inhibited agonist binding to RG, in contrast to their weak inhibition of binding to R. This finding demonstrates, for the first time, that the inhibitory action of a family B GPCR antagonist is dependent upon the conformational state of the receptor. The strong inhibition of peptide agonist binding to RG explains the antagonist properties of the compounds, because this state of the receptor is coupled, via subsequent G protein activation, to intracellular signaling pathways. At the RG state, deviations from competitive behavior were observed: NBI 35965 slowed radiolabeled agonist dissociation and incompletely inhibited 125 Isauvagine binding at high radioligand concentrations. These observations can be explained by strong allosteric inhibition by the nonpeptide antagonist (Appendix) or by a model that assumes competitive inhibition at one of two peptide agonistbinding sites (see above). We could not distinguish these two models because it was not possible to unambiguously define In this study, we have evaluated the functional mechanism of nonpeptide antagonism of the CRF 1 receptor. The molecular mechanism underlying the effects requires further investigation. In our view, the data in this study are consistent with three plausible molecular mechanisms (Fig. 9) . These mechanisms assume that peptide binds to the N-and Jdomains (Perrin and Vale, 1999; Grigoriadis et al., 2001) , that nonpeptide antagonist binds only the J-domain (Liaw et al., 1997a; Nielsen et al., 2000) , and that an allosteric interaction is at least partially involved in the inhibition of peptide binding by nonpeptide antagonist (see above). In mechanism 1, nonpeptide antagonist binds to a site distinct from the peptide-binding site in the J-domain, and allosterically inhibits peptide binding to the J-domain (Fig. 9A) . In mechanism 2, nonpeptide antagonist binding to the J-domain allosterically inhibits peptide binding to the N-domain (Fig.  9B) . In mechanism 3, an extension of mechanism 2, nonpeptide antagonist binds to the same site in the J-domain as the peptide, competitively inhibiting peptide binding to the Jdomain, whereas allosterically inhibiting peptide binding to the N-domain (Fig. 9C ). Molecular biological approaches will be required to distinguish these models. The currently limited data are consistent with mechanism 1: mutation of His 199 (in transmembrane 3) to Val and Met276 (in transmembrane 5) to Ile increased the K i value of NBI 27914 for the CRF 1 receptor (40-and 200-fold, respectively), without affecting the binding affinity of CRF (Liaw et al., 1997a) .
In summary, for the first time we have quantitatively evaluated the inhibitory mechanism of nonpeptide antagonists for the CRF 1 receptor. The allosteric ternary complex model was necessary and sufficient to account for the data for the R state. The compounds are weak allosteric inhibitors of peptide binding to the R state. In contrast, at the RG state nonpeptide antagonists strongly inhibited peptide agonist binding, demonstrating a previously unknown effect of R-G coupling on nonpeptide antagonist activity. The strong inhibitory activity at RG could be explained by either strong allosteric inhibition or competitive inhibition at one of the two peptide-binding sites. Strong inhibition of peptide binding to RG explains the antagonist activity of the compounds. These findings will be relevant to the further study and discovery of nonpeptide antagonists for the CRF 1 receptor, and potentially for other family B GPCRs.
Appendix

Description of the Allosteric Ternary Complex
Model. Numerous observations in this study suggest an allosteric interaction between the binding of nonpeptide antagonists and peptide ligands to the CRF 1 receptor. (Allosteric modulation is defined here as the ability of ligand binding to one site to influence the binding of ligand to a second, at least partially distinct site on the receptor.) For other GPCRs allosteric modulation is well described by a simple model, the allosteric ternary complex model (Stockton et al., 1983; Ehlert, 1988; Lazareno and Birdsall, 1995) shown in Scheme 1.
As derived previously (Lazareno and Birdsall, 1995) , the equation describing the effect of N on the binding of L is as follows:
where [R TOT ] is the total receptor concentration. The equation describing the effect of L on the binding of N is as follows: Fig. 9 . Potential molecular models of nonpeptide antagonist action at the CRF 1 receptor. These models of nonpeptide ligand and peptide interaction with the receptor are consistent with the data in the present study. Peptide ligand is assumed to consist of two binding regions, which interact with two corresponding binding domains of the receptor (the N-and the J-domain). Nonpeptide antagonist (NPA) is assumed to bind only the J-domain. The dashed line indicates an allosteric interaction between spatially distinct binding sites. A, nonpeptide antagonist allosterically inhibits peptide binding to the J-domain. B, nonpeptide antagonist allosterically inhibits peptide binding to the N-domain. C, nonpeptide antagonist competitively inhibits peptide binding to the J-domain and allosterically inhibits peptide binding to the N-domain. An allosteric component was included in each mechanism because allosteric inhibition was demonstrated for the R state. Note that the figure is a schematic representation and so may not accurately reflect the precise location of the receptor's binding sites. 
In the experiments in Fig. 2 (Fig. 1A) , consistent with negative cooperativity. The data were fitted to eq. 1 using Prism 3.0, to obtain estimates of K N and ␣ (fitted values in Table 1 ). The fitted pK N value was in good agreement with the pK i value of each compound for displacing [ 3 H]NBI 35965 binding (Table  1 ). The ␣ value was similar for all four antagonists (0.54-0.65; Table 1 ), indicating a similar extent of negative cooperativity for the ligands. The negative cooperativity was weak: the ␣ value of 0.65 for NBI 35965 indicates that binding of the ligand reduces the affinity of 125 I-astressin from 70 to 110 pM.
The allosteric effect of NBI 35965 on peptide agonist binding to the R state was quantified by fitting the data of Fig. 2 to eq. 3. The data for agonist binding alone and in the presence of the three concentrations of NBI 35965 were analyzed simultaneously using SigmaPlot 2000 (SPSS Science, Chicago, IL), with [L] and [N] as independent variables. NBI 35965 exerted negative cooperativity on the binding of all three peptide agonists (sauvagine, CRF, and UCN I; Table 2 ). This negative cooperativity was significantly stronger between NBI 35965 and peptide agonists (␣ values of 0.11-0.33) than between NBI 35965 and the peptide antagonist astressin (␣ ϭ 0.65; Table 1 ). In addition, ␣ differed significantly between the different agonists; negative cooperativity for CRF or UCN I (0.11 and 0.14, respectively) was stronger than that for sauvagine (0.33; Table 2 ). However, in all cases the negative cooperativity at the R state of the CRF 1 receptor was weak; the lowest ␣ value, 0.11 for NBI 35965 and UCN I, indicates that binding of NBI 35965 to the receptor reduced the UCN I binding affinity by only 9-fold.
As described above, the model predicts that the cooperative effect of N binding on the affinity of L for R is the same as the effect of L binding on the affinity of N for R (Trankle et al., 1999 ). This prediction was tested by measuring the effect of unlabeled peptides on equilibrium binding of [ 3 H]NBI 35965 to the R state (Fig. 4B) We next considered the allosteric interaction between NBI 35965 and peptide ligands in radioligand dissociation experiments, for the R state of the CRF 1 receptor. In the allosteric ternary complex model, binding of N can affect the dissociation of L from the receptor because N can bind the RL com- model, because the negative cooperativity is high, and the concentration of radioligand (realative to its K d ) is low.
